WORTHING, UNITED KINGDOM--(Marketwired - May 9, 2016) - Allergy Therapeutics (
AIM: AGY
9 May 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Allergy Therapeutics announces positive top-line results from the PQBirch204 Phase II study for birch-induced seasonal allergic rhinitis
Allergy Therapeutics, (
The study randomised 371 patients into six cumulative dosing regimens plus a placebo, evaluating the change in Total Symptom Score (TSS) following a conjunctival provocation test (CPT) with the objective to achieve a dose recommended for Phase III development.
Results summary of the PQBirch 204 Phase II study programme
Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/5849X_1-2016-5-9.pdf
This information is provided by RNS
The company news service from the London Stock Exchange
Contact Information:
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet
Chief Executive Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton
allergytherapeutics@consilium-comms.com